SEC Form 4 · accession 0001193125-26-271069
FATE THERAPEUTICS INC · FATE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Hamill
Director
Period of report
Jun 12, 2026
Accepted (ET)
Jun 15, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001434316
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.06 | Jun 12, 2026 | A | 175,800 | A | — | Jun 12, 2036 | Common Stock | 175,800 | 175,800 | D |
Explanation of responses
- F1This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for an equity grant upon a director's appointment or election to the Board of Directors.
- F2The shares subject to this option shall vest in 36 equal monthly installments following June 12, 2026, such that all of the shares shall be fully vested and exercisable on June 12, 2029, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.